Zydus Lifesciences Limited (BOM:532321)

Market Cap	910.34B -1.9%
Revenue (ttm)	260.89B +17.3%
Net Income	49.38B +8.9%
EPS	49.07 +9.0%
Shares Out	n/a
PE Ratio	18.43
Forward PE	21.27
Dividend	11.00 (1.24%)
Ex-Dividend Date	Jul 25, 2025

Volume	24,750
Average Volume	33,046
Open	922.85
Previous Close	920.80
Day's Range	897.50 - 922.85
52-Week Range	797.05 - 1,059.00
Beta	n/a
RSI	51.41
Earnings Date	Feb 9, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In fiscal year 2025, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.